To receive all of the company’s financial communications in real time, please register directly by email to the following address: [email protected]
TME Pharma NV (Euronext Growth Paris: ALTME), a biotechnology company specializing in the development of novel therapies for the treatment of cancer by targeting the tumor microenvironment (TME), announces the successful closing of a private placement financing of a gross amount of 1.48 million euros from a group of new investors. Proceeds from this offering will be used to repurchase all outstanding convertible bonds held by Atlas Special Opportunities, LLC (ASO), thereby terminating TME Pharma’s convertible bond financing program.